A therapy-resistant chronic leg ulcer treated successfully with topical basic fibroblast growth factor

J Int Med Res. 2003 Mar-Apr;31(2):149-51. doi: 10.1177/147323000303100212.

Abstract

We report a patient with rheumatoid arthritis who had a chronic leg ulcer with long-standing resistance to therapy. Topical basic fibroblast growth factor (bFGF) at a dose of 30 micrograms/day for 3 months was clinically effective in reducing the ulcer area by promoting angiogenesis, re-epithelization, granulation and scar formation. bFGF may be an effective treatment for therapy-resistant leg ulcers.

Publication types

  • Case Reports

MeSH terms

  • Administration, Topical
  • Adult
  • Arthritis, Rheumatoid / complications
  • Chronic Disease
  • Female
  • Fibroblast Growth Factor 2 / administration & dosage*
  • Humans
  • Leg Ulcer / complications
  • Leg Ulcer / drug therapy*
  • Recurrence
  • Remission Induction / methods
  • Treatment Failure
  • Treatment Outcome

Substances

  • Fibroblast Growth Factor 2